Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer

← catalyst calendar

NCT05775159 · readout in 69 d

Sponsored by AstraZeneca (industry) · AZN — their whole pipeline →.

Phase

Phase 2

Status

Active, not recruiting

Study type

Interventional

Design

Non randomized · None · Treatment

Enrollment

294estimated

Sites

Countries

China, Hong Kong, Italy +6

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

2023-04-24

actual

When the study began enrolling

Primary completion

2026-10-27

estimated

The date the last participant is measured for the primary outcome — the readout window

Study completion

2027-10-28

estimated

The whole study's end, after follow-up

First posted

2023-03-20

actual

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2026-07-02

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Conditions

Hepatocellular Carcinoma
Biliary Tract Cancer

Interventions

Drug: Volrustomig
Drug: Bevacizumab
Drug: Lenvatinib
Drug: Rilvegostomig
Drug: Gemcitabine
Drug: Cisplatin

Primary outcomes

what the primary-completion date above is the date OF

Objective response rate (ORR)

measured Through study completion, an average of 2 years

The number of participants with adverse events/serious adverse events

measured Through study completion, an average of 2 years

Progression free survival (PFS)

measured Through study completion, an average of 2 years

Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed